[HTML][HTML] Symptoms, Viral Loads, and Rebound Among Coronavirus Disease 2019 (COVID-19) Outpatients Treated With Nirmatrelvir/Ritonavir Compared With …
SE Smith-Jeffcoat, JE Biddle, HK Talbot… - Clinical Infectious …, 2023 - academic.oup.com
Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
[HTML][HTML] Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed …
WC Kwok, MF Tsoi, SHI Leung, CK Tsui, TCC Tam… - Viruses, 2023 - mdpi.com
While molnupiravir (MOV) and nirmatrelvir–ritonavir (NMV-r) were developed for treatment of
mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among …
mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among …
[PDF][PDF] N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
A Zibat, X Zhang, A Dickmanns, KM Stegmann… - Iscience, 2023 - cell.com
Summary N4-hydroxycytidine (NHC), the active compound of the drug Molnupiravir, is
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants
Y Wang, D Zhao, X Chen, X Liu… - Influenza and other …, 2023 - Wiley Online Library
Background The pandemic of coronavirus disease 2019 (COVID‐19) has caused heavy
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
[HTML][HTML] Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
JA Lewnard, JM McLaughlin, D Malden… - The Lancet Infectious …, 2023 - thelancet.com
Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
[HTML][HTML] Is azvudine comparable to nirmatrelvir-ritonavir in real-world efficacy and safety for hospitalized patients with COVID-19? A retrospective cohort study
Q Zhao, B Zheng, B Han, P Feng, Z Xia, H Jiang… - Infectious Diseases and …, 2023 - Springer
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …
in China due to their earlier approval by the National Medical Products Administration …
Infectious disease modeling
X Liu, P Stechlinski - A Hybrid System Approach. Cham: Springer, 2017 - Springer
Human life expectancy has increased over the past three centuries, from approximately 30
years in 1700 to approximately 70 years in 1970 [4]; one of the main factors of this …
years in 1700 to approximately 70 years in 1970 [4]; one of the main factors of this …
Weekly symptom profiles of nonhospitalized individuals infected with SARS‐CoV‐2 during the Omicron outbreak in Hong Kong: A retrospective observational study …
J Luo, J Zhang, HT Tang, HK Wong… - Journal of Medical …, 2023 - Wiley Online Library
Abstract Omicron BA. 2.2 is the dominant variant in the Hong Kong outbreak since
December 31, 2021. There is no study reporting the weekly symptom profile after infection …
December 31, 2021. There is no study reporting the weekly symptom profile after infection …
[HTML][HTML] Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: systematic review and …
KM Souza, G Carrasco, R Rojas-Cortés… - Plos one, 2023 - journals.plos.org
Objective To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …